AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03563014 — intervention group
Intervention type: DRUG
Intervention: Radium-223 (Xofigo, Bay88-8223)
Description: Follow the physician's prescription in routine clinical practice.
Study NCT01915810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete SCwPA intervention
Study NCT01915810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01915810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01915810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Receive nicotine patch
Study NCT01915810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Receive nicotine patch
Study NCT01915810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01915810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01915810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive smoking cessation counseling
Study NCT00679393 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction internal fixation
Description: Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
Study NCT00679393 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fusion
Description: Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
Study NCT04249154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eligard
Description: Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
Study NCT01206543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative imaging using 1.5T MRI
Description: Intraoperative imaging and determination of degree of resection / complete tumor removal
Study NCT01304238 — intervention group
Intervention type: DRUG
Intervention: lepirudin
Description: lepirudin
Study NCT01304238 — intervention group
Intervention type: DRUG
Intervention: danaparoid
Description: danaparoid
Study NCT01304238 — intervention group
Intervention type: DRUG
Intervention: argatroban
Description: argatroban
Study NCT01304238 — intervention group
Intervention type: DRUG
Intervention: fondaparinux
Description: fondaparinux
Study NCT02470156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Arm (Intervention)
Description: The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
Study NCT02470156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Arm (Comparison)
Description: The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
Study NCT04345757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise
Description: The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
Study NCT02139293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeStim
Description: Intermittent auricular vagus nerve stimulation at different ear points
Study NCT02725346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acromioplasty with planning
Study NCT02725346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acromioplasty without planning
Study NCT03566446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CALRLong36 peptide
Description: 200 ug CALRLong36 peptide in water mixed with 500ul montanide
Study NCT01893294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IT
Study NCT01893294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01893294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01893294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04369716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole oranges
Description: Navel oranges (227 g total)
Study NCT04369716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Apples
Description: Red Delicious apple with skin (230 g)
Study NCT04369716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice + orange pomace
Description: Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
Study NCT04369716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple juice + apple pomace
Description: Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
Study NCT04369716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Orange Juice (250 g)
Study NCT04369716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: Apple Juice (235 g)
Study NCT02594761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hercules
Description: Powder Concentrate for Intravenous Infusion, 150 mg/vial
Study NCT02594761 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin EU
Description: Powder for Concentrate for Solution for Infusion, 150 mg/vial
Study NCT02594761 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin US
Description: Intravenous Infusion, 440 mg/vial
Study NCT04200976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-CABA
Description: Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions.
Study NCT04200976 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
Study NCT03429231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol
Description: Patients in the active group will take one tablet a day orally
Study NCT04033185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality, robot assisted gait training
Description: study group: 15 sessions virtual reality, robot assisted gait training
Study NCT04033185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
Study NCT04033185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
Study NCT01786473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testogel 1%
Study NCT01786473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02608593 — intervention group
Intervention type: PROCEDURE
Intervention: Strattice
Description: Implant based reconstruction with strattice cover of part or all of implant
Study NCT02977585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10 cmH2O peep
Description: positive end expiratory pressure
Study NCT00798915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline
Study NCT00798915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
Study NCT00798915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
Study NCT00798915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
Study NCT01915810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive smoking cessation counseling
Study NCT03923166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg qd
Study NCT03923166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 500mg tid
Study NCT03216525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvimopan
Description: To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
Study NCT03216525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
Study NCT02819011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MBB AFO
Description: Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
Study NCT02819011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects will be provided with a pair of New Balance 813 shoes
Study NCT01962350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Transcranial Magnetic Stimulation
Description: H1-Coil deep brain rTMS at cortex prefrontal.
Study NCT02504593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis
Description: The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
Study NCT01748734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01748734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01748734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo cognitive behavioral therapy
Study NCT01748734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Undergo cognitive behavioral therapy
Study NCT03964831 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200TxE
Description: The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
Study NCT03964831 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200DTx
Description: The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
Study NCT01314183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
Study NCT01314183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
Study NCT01314183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
Study NCT01314183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
Study NCT00672893 — intervention group
Intervention type: OTHER
Intervention: Vibration Response Imaging
Description: 12 seconds of recording lung sounds
Study NCT00736021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
Study NCT01748747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC
Study NCT01748747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC
Study NCT01748747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01748747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gag:267-274 peptide vaccine
Description: Given SC
Study NCT01748747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resiquimod
Description: Applied topically
Study NCT00247663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT01724346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
Study NCT01724346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next-line ibrutinib
Description: Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
Study NCT03208829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises
Description: Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
Study NCT03208829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative guidance
Description: Group 2 will receive only guidelines regarding postoperative care.
Study NCT02952508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 single dose
Description: Radiopharmaceutical
Study NCT02952508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 multiple dose
Description: Radiopharmaceutical
Study NCT02952508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 fractionated dose
Description: Radiopharmaceutical
Study NCT03545555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale Preparation Kale Powder
Description: Effect of kale preparation kale powder on lipid status
Study NCT03545555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale Preparation Kale Extract
Description: Effect of kale preparation kale extract on lipid status
Study NCT03545555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale Preparation Flavonoid Extract
Description: Effect of kale preparation flavonoid extract on lipid status
Study NCT03545555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effect of placebo on lipid status
Study NCT00536744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acoustical pulse energy (extracorporeal shockwave)
Description: Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
Study NCT00536744 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Non-energized (inactive - Sham) application + standard of care
Study NCT00417326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5046Na
Description: twenty four hour infusion at 0 mg/kg/hr for 14 days
Study NCT00417326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5046Na
Description: twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
Study NCT00595088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC-819/PEI
Description: Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
Study NCT03391362 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
Study NCT03435211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00006
Description: Noninvasive pulse oximeter sensor
Study NCT04097301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
Description: Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
Study NCT04447664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclouded telespirometry system
Description: Components of the system: Portable digital ultrasonic spirometer (Uscom SpiroSonic MOBILE), android mobile application, clinical web cloud application
Study NCT00840151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
Study NCT04020809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Anti-PD-L1 monoclonal antibody